US Department of Defense awards Ology Bioservices $27m contract

The contract has been established for Ology to establish their proprietary Veroplex cell platform for rapid response to emerging viral diseases

The Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies has awarded a contract valued at $27.3 million to Ology Bioservices a biologics CDMO.

The contract with the US-based company is to establish their proprietary Veroplex cell platform for rapid response to emerging viral diseases.

Peter Khoury, President and CEO of Ology Bioservices, said: "The Veroplex platform has the possibility to allow rapid vaccine development for many potential emerging viral infectious diseases."

Khoury explained: "There is solid evidence that this Vero cell line, when combined with recent innovations in vaccine manufacturing technology, may be valuable in quickly manufacturing vaccines and other biologics in a very small footprint."